carbmaster
New Member
The full Lancet paper for eloralintide phase 2 trials was released (LY3841136), and the data is pretty striking. For those not tracking, this is Lilly’s selective amylin agonist. Unlike Novo’s cagrilintide (which hits AMYR and CTR), eloralintide is engineered to be highly selective for the amylin 1 receptor (AMY1R).
At 48 weeks, the 9 mg dose hit -20% body weight (-21.3 kg), with the 3→9 mg escalation group delivering -16.4% but with notably fewer sides.
Cagrilintide (Novo): Non-selective. It hits amylin receptors and the calcitonin receptor (CTR) . Why does that matter? Activating CTR is linked to calcium lowering and potentially bone turnover issues. Preclinical data suggests cagrilintide triggers more "conditioned taste avoidance" (a marker for nausea) .
Eloralintide (Lilly): Selective for AMY1R . It avoids CTR.
Result: In head-to-head rat studies, eloralintide matched cagrilintide for weight loss but with "improved GI tolerability" and "reduced loss of lean mass" .
Human translation: Less nausea, less fatigue, and maybe better muscle preservation.
Lilly isn't stupid. They know Novo has CagriSema (Cagri + Semaglutide) filing for FDA right now with 22.7% loss .
Lilly’s counter-punch? They are already running Phase 2 trials combining eloralintide + tirzepatide .
Think about that stack:
Tirzepatide (GIP/GLP-1): Drives the bulk of loss via incretins.
Eloralintide (Amylin): Adds a separate pathway (satiety/gastric emptying) via AMY1R.
But the real speculation is the triple agonist: Retatrutide (GLP-1/GIP/GCGR) + Eloralintide .
Reta already hit 24.2% in Phase 2, and around 28% in phase 3. Add selective amylin agonism on top of that? You might finally crack 25-30% average loss (maybe even more).
"Lilly is currently investigating eloralintide alone (as a monotherapy) and in combination with tirzepatide for the treatment of obesity or overweight with at least one obesity-related comorbidity in Phase 2 trials. Lilly plans to initiate Phase 3 clinical studies of eloralintide as a monotherapy for the treatment of obesity by the end of 2025 and is evaluating its use as a complimentary treatment to incretin therapy"
Right now, the grey market is flooded with Cagrilintide. But cagri has downsides—higher nausea, appetite suppression that feels "dirty" compared to GLP-1s. Issues with PH and potential brain Fibrils. Lots of people reporting extreme fatigue. Just Cag just does not seem like a good compound.
We can get our "research" labs in China to start producing this peptide. One supplier know for making bulk API on the underground forum has the sequence and can produce it. If we start requesting this product from our guys in China im sure we will be able to get lyophilized products in no time. Plus Elora is miles better then the currently produced Cag.
Unless i'm missing something as to why they are not already mass producing it. It seems like a very promising compound. Why use an inferior product when we can get a much better product if we just do a little bit of pestering of these sources.
Also note no plateau in weight loss.
https://diabetesjournals.org/diabetes/article-split/74/Supplement_1/849-P/159927/
At 48 weeks, the 9 mg dose hit -20% body weight (-21.3 kg), with the 3→9 mg escalation group delivering -16.4% but with notably fewer sides.
Cagrilintide (Novo): Non-selective. It hits amylin receptors and the calcitonin receptor (CTR) . Why does that matter? Activating CTR is linked to calcium lowering and potentially bone turnover issues. Preclinical data suggests cagrilintide triggers more "conditioned taste avoidance" (a marker for nausea) .
Eloralintide (Lilly): Selective for AMY1R . It avoids CTR.
Result: In head-to-head rat studies, eloralintide matched cagrilintide for weight loss but with "improved GI tolerability" and "reduced loss of lean mass" .
Human translation: Less nausea, less fatigue, and maybe better muscle preservation.
Lilly isn't stupid. They know Novo has CagriSema (Cagri + Semaglutide) filing for FDA right now with 22.7% loss .
Lilly’s counter-punch? They are already running Phase 2 trials combining eloralintide + tirzepatide .
Think about that stack:
Tirzepatide (GIP/GLP-1): Drives the bulk of loss via incretins.
Eloralintide (Amylin): Adds a separate pathway (satiety/gastric emptying) via AMY1R.
But the real speculation is the triple agonist: Retatrutide (GLP-1/GIP/GCGR) + Eloralintide .
Reta already hit 24.2% in Phase 2, and around 28% in phase 3. Add selective amylin agonism on top of that? You might finally crack 25-30% average loss (maybe even more).
"Lilly is currently investigating eloralintide alone (as a monotherapy) and in combination with tirzepatide for the treatment of obesity or overweight with at least one obesity-related comorbidity in Phase 2 trials. Lilly plans to initiate Phase 3 clinical studies of eloralintide as a monotherapy for the treatment of obesity by the end of 2025 and is evaluating its use as a complimentary treatment to incretin therapy"
Right now, the grey market is flooded with Cagrilintide. But cagri has downsides—higher nausea, appetite suppression that feels "dirty" compared to GLP-1s. Issues with PH and potential brain Fibrils. Lots of people reporting extreme fatigue. Just Cag just does not seem like a good compound.
We can get our "research" labs in China to start producing this peptide. One supplier know for making bulk API on the underground forum has the sequence and can produce it. If we start requesting this product from our guys in China im sure we will be able to get lyophilized products in no time. Plus Elora is miles better then the currently produced Cag.
Unless i'm missing something as to why they are not already mass producing it. It seems like a very promising compound. Why use an inferior product when we can get a much better product if we just do a little bit of pestering of these sources.
Also note no plateau in weight loss.
https://diabetesjournals.org/diabetes/article-split/74/Supplement_1/849-P/159927/
